Announcements Trials
Browse Landscape

Status

Completed 2Unknown 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 55Observational 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 2Leukemia 1

Interventions

Surveys and Questionnaires 286Blood Specimen Collection 145Gene Expression Profiling 96Interviews as Topic 83Immunohistochemistry 78Polymerase Chain Reaction 64Surgical Procedures, Operative 62Magnetic Resonance Spectroscopy 58Microarray Analysis 55Flow Cytometry 53Radiotherapy 49Amplified Fragment Length Polymorphism Analysis 48Drug Therapy 46Observation 45Biopsy 42Reverse Transcriptase Polymerase Chain Reaction 39Bevacizumab 39Data Collection 35Sorafenib 29Psychiatric Rehabilitation 29Nivolumab 28palbociclib 26In Situ Hybridization, Fluorescence 26Rituximab 25Therapeutics 24Neoadjuvant Therapy 24Hepatectomy 24Docetaxel 24Colonoscopy 24Sunitinib 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Observational × Gemtuzumab × Clear all
NCT04337138 2021-08-09

A Study Of Treatment Patterns And Clinical Outcomes In Patients Diagnosed With Acute Myeloid Leukemia Who Received Mylotarg in the Real-World

Pfizer

Completed
32 enrolled 18 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00161668 2007-03-15

Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care

Wyeth is now a wholly owned subsidiary of Pfizer

Completed
500 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡